Diabetes Care, Vol 22, Issue 7 1137-1143, Copyright © 1999 by American Diabetes Association

ARTICLES

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients

MB Toft-Nielsen, S Madsbad and JJ Holst
Department of Endocrinology, Hvidovre Hospital, Denmark.

OBJECTIVE: The gut hormone glucagon-like peptide 1 (GLP-1) has insulinotropic and anorectic effects during intravenous infusion and has been proposed as a new treatment for type 2 diabetes and obesity. The effect of a single subcutaneous injection is brief because of rapid degradation. We therefore sought to evaluate the effect of infusion of GLP-1 for 48 h in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: We infused GLP-1 (2.4 pmol.kg-1.min-1) or saline subcutaneously for 48 h in randomized order in six patients with type 2 diabetes to evaluate the effect on appetite during fixed energy intake and on plasma glucose, insulin, glucagon, postprandial lipidemia, blood pressure, heart rate, and basal metabolic rate. RESULTS: The infusion resulted in elevations of the plasma concentrations of intact GLP-1 similar to those observed after intravenous infusion of 1.2 pmol.kg-1.min-1, previously shown to lower blood glucose effectively in type 2 diabetic patients. Fasting plasma glucose (day 2) decreased from 14.1 +/- 0.9 (saline) to 12.2 +/- 0.7 mmol/l (GLP-1), P = 0.009, and 24-h mean plasma glucose decreased from 15.4 +/- 1.0 to 13.0 +/- 1.0 mmol/l, P = 0.0009. Fasting and total area under the curve for insulin and C-peptide levels were significantly higher during the GLP-1 administration, whereas glucagon levels were unchanged. Neither triglycerides nor free fatty acids were affected. GLP-1 administration decreased hunger and prospective food intake and increased satiety, whereas fullness was unaffected. No side effects during GLP-1 infusion were recorded except for a brief cutaneous reaction. Basal metabolic rate and heart rate did not change significantly during GLP-1 administration. Both systolic and diastolic blood pressure tended to be lower during the GLP-1 infusion. CONCLUSIONS: We conclude that 48-h continuous subcutaneous infusion of GLP-1 in type 2 diabetic patients 1) lowers fasting as well as meal-related plasma glucose, 2) reduces appetite, 3) has no gastrointestinal side effects, and 4) has no negative effect on blood pressure.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. F Van Gaal, S. W Gutkin, and M. A Nauck Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? Eur. J. Endocrinol., June 1, 2008; 158(6): 773 - 784. [Abstract] [Full Text] [PDF]

				G. C. Mistry, A. L. Maes, K. C. Lasseter, M. J. Davies, K. M. Gottesdiener, J. A. Wagner, and G. A. Herman Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension J. Clin. Pharmacol., May 1, 2008; 48(5): 592 - 598. [Abstract] [Full Text] [PDF]

				S. Lerche, B. Brock, J. Rungby, H. E. Botker, N. Moller, A. Rodell, B. M. Bibby, J. J. Holst, O. Schmitz, and A. Gjedde Glucagon-Like Peptide-1 Inhibits Blood-Brain Glucose Transfer in Humans Diabetes, February 1, 2008; 57(2): 325 - 331. [Abstract] [Full Text] [PDF]

				L. Simonsen, S. Pilgaard, C. Orskov, M. M. Rosenkilde, B. Hartmann, J. J. Holst, and C. F. Deacon Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G288 - G295. [Abstract] [Full Text] [PDF]

				B. Laferrere, S. Heshka, K. Wang, Y. Khan, J. McGinty, J. Teixeira, A. B. Hart, and B. Olivan Incretin Levels and Effect Are Markedly Enhanced 1 Month After Roux-en-Y Gastric Bypass Surgery in Obese Patients With Type 2 Diabetes Diabetes Care, July 1, 2007; 30(7): 1709 - 1716. [Abstract] [Full Text] [PDF]

				T. H Claus, C. Q Pan, J. M Buxton, L. Yang, J. C Reynolds, N. Barucci, M. Burns, A. A Ortiz, S. Roczniak, J. N Livingston, et al. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes J. Endocrinol., February 1, 2007; 192(2): 371 - 380. [Abstract] [Full Text] [PDF]

				P. L. BRUBAKER The Glucagon-Like Peptides: Pleiotropic Regulators of Nutrient Homeostasis Ann. N.Y. Acad. Sci., July 1, 2006; 1070(1): 10 - 26. [Abstract] [Full Text] [PDF]

				L.-X. Li, P. E. MacDonald, D. S. Ahn, G. Y. Oudit, P. H. Backx, and P. L. Brubaker Role of Phosphatidylinositol 3-Kinase{gamma} in the {beta}-Cell: Interactions with Glucagon-Like Peptide-1 Endocrinology, July 1, 2006; 147(7): 3318 - 3325. [Abstract] [Full Text] [PDF]

				P. Vazquez, I. Roncero, E. Blazquez, and E. Alvarez The cytoplasmic domain close to the transmembrane region of the glucagon-like peptide-1 receptor contains sequence elements that regulate agonist-dependent internalisation J. Endocrinol., July 1, 2005; 186(1): 221 - 231. [Abstract] [Full Text] [PDF]

				T. Nystrom, M. K. Gutniak, Q. Zhang, F. Zhang, J. J. Holst, B. Ahren, and A. Sjoholm Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease Am J Physiol Endocrinol Metab, December 1, 2004; 287(6): E1209 - E1215. [Abstract] [Full Text] [PDF]

				J. J. Meier, B. Gallwitz, B. Kask, C. F. Deacon, J. J. Holst, W. E. Schmidt, and M. A. Nauck Stimulation of Insulin Secretion by Intravenous Bolus Injection and Continuous Infusion of Gastric Inhibitory Polypeptide in Patients With Type 2 Diabetes and Healthy Control Subjects Diabetes, December 1, 2004; 53(suppl_3): S220 - S224. [Abstract] [Full Text] [PDF]

				M. Zander, A. Christiansen, S. Madsbad, and J. Juul Holst Additive Effects of Glucagon-Like Peptide 1 and Pioglitazone in Patients With Type 2 Diabetes Diabetes Care, August 1, 2004; 27(8): 1910 - 1914. [Abstract] [Full Text] [PDF]

				H. Harder, L. Nielsen, T. D.T. Thi, and A. Astrup The Effect of Liraglutide, a Long-Acting Glucagon-Like Peptide 1 Derivative, on Glycemic Control, Body Composition, and 24-h Energy Expenditure in Patients With Type 2 Diabetes Diabetes Care, August 1, 2004; 27(8): 1915 - 1921. [Abstract] [Full Text] [PDF]

				S. Madsbad, O. Schmitz, J. Ranstam, G. Jakobsen, and D. R. Matthews Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial Diabetes Care, June 1, 2004; 27(6): 1335 - 1342. [Abstract] [Full Text] [PDF]

				M. R. Druce, C. J. Small, and S. R. Bloom Minireview: Gut Peptides Regulating Satiety Endocrinology, June 1, 2004; 145(6): 2660 - 2665. [Abstract] [Full Text] [PDF]

				G. S. Meneilly, N. Greig, H. Tildesley, J. F. Habener, J. M. Egan, and D. Elahi Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes Diabetes Care, October 1, 2003; 26(10): 2835 - 2841. [Abstract] [Full Text] [PDF]

				D. J. Drucker Enhancing Incretin Action for the Treatment of Type 2 Diabetes Diabetes Care, October 1, 2003; 26(10): 2929 - 2940. [Abstract] [Full Text] [PDF]

				A. M. Chang, G. Jakobsen, J. Sturis, M. J. Smith, C. J. Bloem, B. An, A. Galecki, and J. B. Halter The GLP-1 Derivative NN2211 Restores {beta}-Cell Sensitivity to Glucose in Type 2 Diabetic Patients After a Single Dose Diabetes, July 1, 2003; 52(7): 1786 - 1791. [Abstract] [Full Text] [PDF]

				R. Gros, X. You, L. L. Baggio, M. G. Kabir, A. M. Sadi, I. N. Mungrue, T. G. Parker, Q. Huang, D. J. Drucker, and M. Husain Cardiac Function in Mice Lacking the Glucagon-Like Peptide-1 Receptor Endocrinology, June 1, 2003; 144(6): 2242 - 2252. [Abstract] [Full Text] [PDF]

				J. M. Egan, G. S. Meneilly, and D. Elahi Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes Am J Physiol Endocrinol Metab, June 1, 2003; 284(6): E1072 - E1079. [Abstract] [Full Text] [PDF]

				C. Thomsen, H. Storm, J. J Holst, and K. Hermansen Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes Am. J. Clinical Nutrition, March 1, 2003; 77(3): 605 - 611. [Abstract] [Full Text] [PDF]

				J.-G. Kim, L. L. Baggio, D. P. Bridon, J.-P. Castaigne, M. F. Robitaille, L. Jette, C. Benquet, and D. J. Drucker Development and Characterization of a Glucagon-Like Peptide 1-Albumin Conjugate: The Ability to Activate the Glucagon-Like Peptide 1 Receptor In Vivo Diabetes, March 1, 2003; 52(3): 751 - 759. [Abstract] [Full Text] [PDF]

				I. N. Legakis, C. Tzioras, and C. Phenekos Decreased Glucagon-Like Peptide 1 Fasting Levels in Type 2 Diabetes Diabetes Care, January 1, 2003; 26(1): 252 - 252. [Full Text] [PDF]

				P. E. MacDonald, W. El-kholy, M. J. Riedel, A. M. F. Salapatek, P. E. Light, and M. B. Wheeler The Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion Diabetes, December 1, 2002; 51(90003): S434 - 442. [Abstract] [Full Text] [PDF]

				G. W. Van Citters, M. Kabir, S. P. Kim, S. D. Mittelman, M. K. Dea, P. L. Brubaker, and R. N. Bergman Elevated Glucagon-Like Peptide-1-(7-36)-Amide, but Not Glucose, Associated with Hyperinsulinemic Compensation for Fat Feeding J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5191 - 5198. [Abstract] [Full Text] [PDF]

				B. Elbrond, G. Jakobsen, S. Larsen, H. Agerso, L. B. Jensen, P. Rolan, J. Sturis, V. Hatorp, and M. Zdravkovic Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects Diabetes Care, August 1, 2002; 25(8): 1398 - 1404. [Abstract] [Full Text] [PDF]

				S. Delgado-Aros, D.-Y. Kim, D. D. Burton, G. M. Thomforde, D. Stephens, B. H. Brinkmann, A. Vella, and M. Camilleri Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans Am J Physiol Gastrointest Liver Physiol, March 1, 2002; 282(3): G424 - G431. [Abstract] [Full Text] [PDF]

				C. B. Juhl, M. Hollingdal, J. Sturis, G. Jakobsen, H. Agerso, J. Veldhuis, N. Porksen, and O. Schmitz Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes Diabetes, February 1, 2002; 51(2): 424 - 429. [Abstract] [Full Text] [PDF]

				C. Verdich, A. Flint, J.-P. Gutzwiller, E. Naslund, C. Beglinger, P. M. Hellstrom, S. J. Long, L. M. Morgan, J. J. Holst, and A. Astrup A Meta-Analysis of the Effect of Glucagon-Like Peptide-1 (7-36) Amide on Ad Libitum Energy Intake in Humans J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4382 - 4389. [Abstract] [Full Text] [PDF]

				J. Larsen, B. Hylleberg, K. Ng, and P. Damsbo Glucagon-Like Peptide-1 Infusion Must Be Maintained for 24 h/day to Obtain Acceptable Glycemia in Type 2 Diabetic Patients Who Are Poorly Controlled on Sulphonylurea Treatment Diabetes Care, August 1, 2001; 24(8): 1416 - 1421. [Abstract] [Full Text] [PDF]

				C. M. B. Edwards, S. A. Stanley, R. Davis, A. E. Brynes, G. S. Frost, L. J. Seal, M. A. Ghatei, and S. R. Bloom Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers Am J Physiol Endocrinol Metab, July 1, 2001; 281(1): E155 - E161. [Abstract] [Full Text] [PDF]

				M. Zander, M. Taskiran, M.-B. Toft-Nielsen, S. Madsbad, and J. J. Holst Additive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes Diabetes Care, April 1, 2001; 24(4): 720 - 725. [Abstract] [Full Text]

				D. J. Drucker Minireview: The Glucagon-Like Peptides Endocrinology, February 1, 2001; 142(2): 521 - 527. [Abstract] [Full Text] [PDF]

				R. Perfetti, J. Zhou, M. E. Doyle, and J. M. Egan Glucagon-Like Peptide-1 Induces Cell Proliferation and Pancreatic-Duodenum Homeobox-1 Expression and Increases Endocrine Cell Mass in the Pancreas of Old, Glucose-Intolerant Rats Endocrinology, December 1, 2000; 141(12): 4600 - 4605. [Abstract] [Full Text] [PDF]

				B. Hartmann, M. B. Harr, P. B. Jeppesen, M. Wojdemann, C. F. Deacon, P. B. Mortensen, and J. J. Holst In Vivo and in Vitro Degradation of Glucagon-Like Peptide-2 in Humans J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2884 - 2888. [Abstract] [Full Text]

				T. J. Kieffer and J. Francis Habener The Glucagon-Like Peptides Endocr. Rev., December 1, 1999; 20(6): 876 - 913. [Abstract] [Full Text]

				J. Lovshin, J. Estall, B. Yusta, T. J. Brown, and D. J. Drucker Glucagon-like Peptide (GLP)-2 Action in the Murine Central Nervous System Is Enhanced by Elimination of GLP-1 Receptor Signaling J. Biol. Chem., June 8, 2001; 276(24): 21489 - 21499. [Abstract] [Full Text] [PDF]